MIMEDX GROUP (MDXG) Company Report

MiMedx Group, Inc. (MIMEDX) commented on the Centers for Medicare and Medicaid Services (CMS) CY 2026 Physician Fee Schedule (PFS) final rule, which was published on Friday.
MIMEDX believes the new PFS will help reduce fraud, waste, and abuse in the skin substitute industry, leading to increased market stability and predictability.
CEO Joseph H. Capper stated that the final rule, which aligns with the July proposal, presents a significant opportunity for MIMEDX due to its competitive advantages, including efficient operations, a strong commercial organization, best-in-class technology, a robust IP portfolio, and an excellent balance sheet.
The company plans to leverage its strengths to gain market share as the market adapts to the new reimbursement environment and will continue to advocate for further improvements.

Nov 3, 2025, 2:15 PM

MiMedx Reports Record Q3 2025 Results and Raises Full-Year Guidance

MDXG

Earnings

Guidance Update

Product Launch

MiMedx achieved record Q3 2025 revenue of $114 million, marking 35% year-over-year net sales growth, and reported adjusted EBITDA of $35 million, or 31% of net sales.
The company has raised its full-year 2025 revenue growth guidance to mid to high teens and expects adjusted EBITDA margin to be at least in the mid-20% range.
Net cash increased by $23 million in Q3 to $124 million, with projections to end 2025 with a net cash balance exceeding $150 million.
The surgical business demonstrated 26% growth in Q3 2025, while the wound franchise grew 40%.
MiMedx is preparing for Medicare reimbursement reforms, anticipated to be implemented in early 2026, which include a proposed fixed payment of $125.38 per square centimeter for skin substitutes, and expects to outperform the market following these changes.

Oct 29, 2025, 8:30 PM

MiMedx Group, Inc. Reports Record Q3 2025 Financial Results and Raises Full-Year Outlook

MDXG

Earnings

Guidance Update

Revenue Acceleration/Inflection

MiMedx Group, Inc. reported record net sales of $114 million for the third quarter of 2025, representing a 35% increase year-over-year. This growth was primarily driven by a 40% increase in Wound product sales and a 26% increase in Surgical product sales.
For the third quarter of 2025, the company achieved GAAP net income of $17 million and diluted earnings per share of $0.11.
Adjusted EBITDA for Q3 2025 was $35 million, or 31% of net sales.
As of September 30, 2025, MiMedx Group, Inc. had $142 million in cash and cash equivalents, with a net cash position of $124 million after debt.
The company raised its 2025 financial outlook, now expecting net sales growth in the mid-to-high teens and an Adjusted EBITDA margin of at least mid-20% for the full year.

Oct 29, 2025, 8:07 PM

Earnings Transcripts

Quarterly earnings call transcripts for MIMEDX GROUP.

Get instant answers from SEC filings, earnings calls & more

Get instant analysis when filings drop